Kimelman & Baird’s Regeneron Pharmaceuticals REGN Stock Holding History

Kimelman & Baird’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$20.9M	Sell	27,628 -43	-0.2%	-$32.5K	1.58%	24
2026 Q2	$17.3M	Buy	27,671 +16,815	+155%	+$11.4M	1.27%	27
2026 Q1	$8.39M	Buy	10,856 +10,542	+3,357%	+$8.07M	0.69%	34
2025 Q4	$242K	Buy	314 +260	+481%	+$177K	0.02%	109
2025 Q3	$30.4K	Hold	54	–	–	﹤0.01%	216
2025 Q2	$28.4K	Hold	54	–	–	﹤0.01%	224
2025 Q1	$34.2K	Hold	54	–	–	﹤0.01%	217
2024 Q4	$38.5K	Hold	54	–	–	﹤0.01%	210
2024 Q3	$56.8K	Hold	54	–	–	﹤0.01%	178
2024 Q2	$56.8K	Buy	+54	New	+$52.3K	﹤0.01%	176
2017 Q1	–	Sell	-550	Closed	-$202K	–	124
2016 Q4	$202K	Buy	+550	New	+$209K	0.03%	113

Other funds holding REGN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Kimelman & Baird's REGN Position: Q3 2026 in Review

Kimelman & Baird reduced its Regeneron Pharmaceuticals (REGN) stake by 0.16% in Q3 2026, selling an estimated $32.5K and leaving 27,628 shares worth $20.9M. The position accounts for 1.58% of the portfolio, ranked #24.

Kimelman & Baird first reported a position in REGN in Q4 2016 and has held it in 11 quarters since. 895 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Kimelman & Baird held 27,628 shares of Regeneron Pharmaceuticals worth $20.9M as of Q3 2026.
Kimelman & Baird sold 43 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $32.5K.
Regeneron Pharmaceuticals made up 1.58% of Kimelman & Baird's portfolio in Q3 2026, its #24 holding.
Kimelman & Baird first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 11 quarters since.
895 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Kimelman & Baird's 13F filing for Q3 2026, filed 3 Nov 2026.